Cannabidiol as a suggested candidate for treatment of autism spectrum disorder

Shani Poleg, Pavel Golubchik, Daniel Offen, Abraham Weizman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Autism Spectrum Disorder (ASD) is characterized by persistent deficits in social communication, restricted and repetitive patterns of behavior, interests, or activities and often intellectual disabilities. ASD has a number of prevalent co-morbidities, such as sleep disorders, attention deficit/hyperactivity disorder and epilepsy. No effective treatment for the core symptoms of ASD is currently available. There is increasing interest in cannabinoids, especially cannabidiol (CBD), as monotherapy or add-on treatment for the core symptoms and co-morbidities of ASD. In this review we summarize the available pre-clinical and clinical data regarding the safety and effectiveness of medical cannabis, including CBD, in young ASD patients. Cannabidiol seems to be a candidate for the treatment of ASD. At present, however, there are no convincing pre-clinical or clinical data showing efficacy and safety of cannabinoid treatment in ASD patients.

Original languageEnglish
Pages (from-to)90-96
Number of pages7
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
StatePublished - 8 Mar 2019


  • Autism spectrum disorder
  • CBD
  • Medical cannabis


Dive into the research topics of 'Cannabidiol as a suggested candidate for treatment of autism spectrum disorder'. Together they form a unique fingerprint.

Cite this